$4.1 Billion Acquisition: Angelini Pharma to Buy Catalyst Pharmaceuticals
Summary
Angelini Pharma has announced its definitive agreement to acquire Catalyst Pharmaceuticals for $4.1 billion. This news confirms earlier reports from April 27 that Angelini was exploring a potential acquisition of Catalyst. This is a highly material event for Catalyst Pharmaceuticals, representing a significant premium over its recent market valuation and will likely drive a substantial increase in the stock price. Traders will now focus on the closing of the deal, including regulatory approvals, and any potential for competing bids.
At the time of this announcement, CPRX was trading at $29.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $19.05 to $32.56. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.